GlassScriptPhysician profile
Michelle D Bennett
NPI 1144292012
$3,371.71
in general payments reported to CMS, 2019-2025
19 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $198 · 2022: $629 · 2023: $446 · 2024: $1,618 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,730 · Travel and Lodging: $779 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,730.39 |
| Travel and Lodging | $779.09 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,699.02 | 2023-2024 | Axonics |
| Medtronic, INC. | $448.27 | 2021-2025 | Interstim |
| Bluewind Medical | $262.96 | 2024-2025 | Revi |
| Endo Pharmaceuticals INC. | $141.75 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $122.38 | 2023-2025 | Gemtesa |
| Ferring Pharmaceuticals INC. | $116.89 | 2024 | Adstiladrin |
| Boston Scientific Corporation | $97.44 | 2021-2025 | Axonics |
| Urovant Sciences INC | $78.71 | 2022 | |
| Myovant Sciences INC. | $68.12 | 2021-2022 | |
| Janssen Biotech, INC. | $57.49 | 2021-2024 | Erleada, Akeega |
| Astellas Pharma US INC | $52.07 | 2023 | Xtandi |
| Tolmar Pharmaceuticals, INC. | $45.60 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Urogen Pharma, INC. | $32.18 | 2022-2025 | |
| Novo Nordisk INC | $31.24 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $25.60 | 2022 | |
| Merck Sharp & Dohme LLC | $21.68 | 2024 | Keytruda |
| Pfizer INC. | $20.61 | 2025 | |
| Clarus Therapeutics INC. | $14.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.